Caplin Point Laboratories Ltd logo

Caplin Point Laboratories Ltd

CAPLIPOINT NSE

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

AI Verdict: BUY Confidence: 7%

Caplin Point Laboratories trades at a PE of 27.6x with a 5-year profit CAGR of 22% and ROE consistently above 21%, supported by a virtually debt-free balance sheet. The stock has compounded at 30% CAGR over 5 years and all 2 analyst ratings are unanimous buys, making it a compelling growth story in the niche LatAm/Africa pharma export space.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹19,006 Cr
Volatility
High Risk
P/E Ratio
29.71
EBITDA
₹761 Cr
Return on Equity
19.77%
Debt to Equity
0
Book Value
₹471.83
EPS
₹62.84
52W High
₹2,590
52W Low
₹1,500.3

Technical Indicators

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.9% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

Growth Rate

Revenue Growth
7.54% ↘
Net Income Growth
21.33% ↗
Cash Flow Change
35.80% ↗
ROE
-4.63% ↘
ROCE
-2.26% ↘
EBITDA Margin (Avg.)
-9.60% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
BUY
Risk medium

Caplin Point Laboratories trades at a PE of 27.6x with a 5-year profit CAGR of 22% and ROE consistently above 21%, supported by a virtually debt-free balance sheet. The stock has compounded at 30% CAGR over 5 years and all 2 analyst ratings are unanimous buys, making it a compelling growth story in the niche LatAm/Africa pharma export space.

Bull Case 8
  • Debt-free balance sheet with negligible debt-to-equity, providing significant financial flexibility and resilience against rate cycles
  • Consistent 5-year compounded profit growth of 22% CAGR demonstrates strong earnings momentum and operational leverage
  • 10-year compounded sales growth of 25% reflects a durable and scalable business model in regulated pharma markets
  • 5-year ROE averaging 23% indicates efficient capital allocation and superior return generation versus sector median of ~14-16%
  • Stock price CAGR of 47% over 3 years significantly outperforms the Nifty Pharma index, showing relative alpha generation
  • 100% analyst buy rating (2 out of 2 analysts) signals consensus confidence in near-term earnings trajectory
  • TTM profit growth of 20% outpaces TTM sales growth of 13%, indicating margin expansion and improving operating leverage
  • Market cap of Rs 18,068 crore positions the company in the midcap sweet spot with room for institutional re-rating as coverage expands
Bear Case 8
  • PE of 27.6x is at a premium to the pharma sector average of ~22-24x, limiting margin of safety for new entrants
  • Dividend yield of only 0.17% suggests minimal capital return to shareholders despite strong profitability
  • Only 2 analysts cover the stock, indicating limited institutional scrutiny and potential liquidity risk during sell-offs
  • TTM sales growth has decelerated to 13% from the 5-year CAGR of 16%, pointing to potential volume or pricing headwinds
  • Last year ROE of 21% has declined from the 10-year average of 25%, suggesting diminishing incremental returns on newer capital deployed
  • Price-to-book of 5x implies the market is pricing in sustained high growth — any earnings miss could trigger sharp de-rating
  • Concentration in Latin America and Africa markets exposes the company to currency volatility and regulatory unpredictability in emerging economies
  • 52-week high and low data unavailable (reported as 0), making technical risk-reward assessment difficult for momentum-based investors

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Neutral 1
  • No share encumbrance in FY26 Jun 16

    Caplin Point Laboratories disclosed that no encumbrance was created on promoter shares during FY26, filed under SEBI regulations.

TL;DR: Limited recent news flow for Caplin Point Laboratories. The sole disclosure confirms clean promoter shareholding with no encumbrance in FY26, which is a routine compliance filing. No material headwinds or catalysts are visible from current news; investors should watch for upcoming quarterly results and regulatory developments in the healthcare/pharma space for directional cues.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
389
395
410
436
453
459
483
493
502
510
534
543
600
Expenses
265
269
273
293
308
307
318
331
334
332
345
353
396
Operating Profit
124
127
137
142
145
152
165
162
168
178
189
190
204
OPM %
32%
32%
34%
33%
32%
33%
34%
33%
33%
35%
35%
35%
34%
Other Income
11
12
21
17
17
19
21
31
26
23
30
34
28
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
11
11
12
14
16
16
17
16
17
16
18
19
19
PBT
124
127
146
145
146
154
168
177
177
184
201
204
213
Tax %
18%
18%
20%
18%
17%
19%
22%
21%
18%
18%
20%
19%
19%
Net Profit
101
104
116
120
121
125
131
140
145
151
160
166
173
EPS in Rs
13.45
13.62
15.13
15.43
16.01
16.31
17.21
18.28
18.76
20.1
20.32
21.56
22.38
Figures in ₹ Crores

Profit & Loss

  Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
252
239
402
540
649
863
1,061
1,269
1,467
1,694
1,937
2,187
Expenses
192
175
276
345
417
603
732
874
1,025
1,142
1,287
1,426
Operating Profit
60
64
125
195
232
260
329
395
442
552
651
761
OPM %
24%
27%
31%
36%
36%
30%
31%
31%
30%
33%
34%
35%
Other Income
3
4
10
13
19
41
23
38
55
66
92
116
Interest
1
0
1
1
1
0
2
1
1
1
1
1
Depreciation
8
7
13
19
23
32
37
47
45
53
66
73
PBT
53
60
121
188
227
269
314
386
451
564
677
803
Tax %
23%
24%
21%
23%
22%
20%
20%
20%
16%
18%
20%
19%
Net Profit
41
46
96
145
177
215
251
308
377
461
541
650
EPS in Rs
5.43
6.05
12.65
19.15
23.35
28.42
32.03
39.56
49.57
60.19
70.56
84.36
Div. Payout %
18%
20%
12%
10%
9%
9%
9%
10%
9%
8%
8%
5%
Figures in ₹ Crores

Balance Sheet

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
15
15
15
15
15
15
15
15
15
15
15
15
Reserves
78
113
210
349
582
858
954
1,252
1,649
2,084
2,619
3,571
Borrowings
2
2
1
1
36
113
235
219
222
219
222
5
Other Liabilities
134
137
133
136
109
139
159
250
305
380
352
454
Total Liabilities
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,045
Fixed Assets
113
144
152
169
227
272
305
287
280
453
546
605
CWIP
31
0
3
15
10
20
14
18
221
117
144
209
Investments
0
0
17
47
70
61
11
89
281
376
590
859
Other Assets
85
122
186
269
436
772
1,033
1,343
1,410
1,753
1,928
2,373
Total Assets
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,045
Figures in ₹ Crores

Cash Flow

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
42
68
66
83
45
269
337
271
318
432
523
Investing
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
-333
-582
Financing
-9
-14
-7
-12
90
80
-24
-41
-28
-38
-38
-46
Net Cash Flow
19
23
25
-14
73
70
215
-81
27
-39
61
-106
Free Cash Flow
24
34
43
18
18
-32
195
246
78
173
241
275
CFO/OP
103
92
73
53
54
38
102
106
81
77
86
88
Figures in ₹ Crores

Ratios

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
8
12
30
85
90
97
96
91
98
117
119
138
Inventory Days
37
57
44
44
47
210
139
149
159
183
159
181
Days Payable
112
168
155
144
76
57
68
102
84
116
103
125
Cash Conversion Cycle
-67
-99
-81
-16
61
251
166
138
173
184
175
194
Working Capital Days
-128
-114
-29
47
104
167
145
165
144
166
174
263
ROCE %
68%
62%
68%
63%
45%
33%
28%
28%
26%
26%
26%
25%

Shareholding Pattern

As of Mar 2026
Promoters 70.57%
Public 14.46%
Others 6.68%
FIIs 6.15%
DIIs 2.14%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
69.03%
69.03%
69.03%
68.91%
68.89%
68.88%
68.88%
68.80%
70.66%
70.63%
70.63%
70.62%
70.62%
70.56%
70.56%
70.56%
70.56%
70.56%
70.57%
70.57%
70.57%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
3.09%
2.85%
3.34%
3.37%
3.70%
4.86%
5.73%
6.17%
6.51%
6.59%
6.15%
DIIs
1.28%
1.44%
1.14%
1.16%
1.20%
1.07%
1.12%
1.12%
0.65%
0.26%
0.20%
0.43%
1.09%
1.49%
1.84%
2.11%
2.01%
2.22%
2.10%
2.05%
2.14%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
22.94%
21.69%
20.93%
20.79%
20.79%
20.76%
19.00%
18.91%
18.73%
18.57%
18.31%
18.36%
17.59%
17.50%
17.12%
15.77%
15.11%
14.32%
14.20%
14.13%
14.46%
Others
6.75%
7.85%
8.90%
9.13%
9.12%
9.28%
11.00%
11.17%
9.96%
10.53%
7.77%
7.74%
7.36%
7.08%
6.78%
6.70%
6.59%
6.73%
6.61%
6.65%
6.68%
No. of Shareholders
68,076
69,524
83,462
85,577
83,829
84,868
84,538
82,687
82,146
78,956
78,068
79,438
81,409
80,411
96,123
92,702
96,387
94,169
93,753
93,705
93,896

Documents

Frequently Asked Questions about Caplin Point Laboratories Ltd

What does Caplin Point Laboratories Ltd do?
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Caplin Point Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: CAPLIPOINT and BSE: 524742. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Caplin Point Laboratories Ltd belong to?
Caplin Point Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a market capitalisation of approximately ₹19005.96 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Caplin Point Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd is 29.71. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Over the past 52 weeks, Caplin Point Laboratories Ltd has traded between a low of ₹1,500.3 and a high of ₹2,590. This range helps investors understand the stock's price volatility and recent trading levels.
Does Caplin Point Laboratories Ltd pay dividends?
Yes, Caplin Point Laboratories Ltd has a dividend yield of 0.16%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a Return on Equity (ROE) of 19.77%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Caplin Point Laboratories Ltd on Tapetide?
On Tapetide, you can view Caplin Point Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Website caplinpoint.net
CEO Dr. Sridhar Ganesan
Employees 3,966
Listed 1994-11-16
Face Value ₹ 2
Issued Size 7,60,11,696

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List